Association Between White Blood Cell Count, Epicardial Blood Flow, Myocardial Perfusion, and Clinical Outcomes in the Setting of Acute Myocardial Infarction: A Thrombolysis In Myocardial Infarction 10 Substudy

BackgroundElevation of the white blood cell (WBC) count during acute myocardial infarction (AMI) is associated with adverse outcomes. We examined the relationship between the WBC count and angiographic findings to gain insight into this relationship.Results and MethodsWe evaluated data from 975 patients in the Thrombolysis In Myocardial Infarction (TIMI) 10A and 10B trials. Patients with a closed artery at 60 and 90 minutes had higher a WBC count than patients with an open artery (P =0.02). Likewise, the presence of angiographically apparent thrombus was associated with a higher WBC count (11.5±5.2×109/L, n=290, versus 10.7±3.5×109/L, n=648;P =0.008). In addition, a higher WBC count was associated with poorer TIMI myocardial perfusion grades (4-way P =0.04). Mortality rates were higher in patients with a higher WBC count (0% for WBC count 0 to 5×109/L, 4.9% for WBC count 5 to 10×109/L, 3.8% for WBC count 10 to 15×109/L, 10.4% for WBC count >15×109/L;P =0.03). The development of new congestive heart failure or shock was also associated with a higher WBC count (0% for WBC count 0 to 5×109/L, 5.2% for WBC count 5 to 10×109/L, 6.1% for WBC count 10 to 15×109/L, 17.1% for WBC count >15×109/L;P <0.001), an observation that remained significant in a multivariable model that adjusted for potential confounding variables (odds ratio 1.21, P =0.002). ConclusionsElevation in WBC count was associated with reduced epicardial blood flow and myocardial perfusion, thromboresistance (arteries open later and have a greater thrombus burden), and a higher incidence of new congestive heart failure and death. These observations provide a potential explanation for the higher mortality rate observed among AMI patients with elevated WBC counts and helps explain the growing body of literature that links inflammation and cardiovascular disease.

[1]  C M Gibson,et al.  Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. , 2000, Circulation.

[2]  Jeffrey M. Hausdorff,et al.  Neutrophilia and congestive heart failure after acute myocardial infarction. , 2000, American heart journal.

[3]  C. Cerletti,et al.  Recent Advances in Platelet-Polymorphonuclear Leukocyte Interaction , 1999, Pathophysiology of Haemostasis and Thrombosis.

[4]  M. Domanski,et al.  White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD]) , 1999, The American journal of cardiology.

[5]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[6]  E. Braunwald,et al.  Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. , 1999, Circulation.

[7]  R. Giugliano,et al.  TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. , 1998, Circulation.

[8]  F. Neumann,et al.  Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction. , 1998, The American journal of cardiology.

[9]  P. Ridker,et al.  Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. , 1998, Circulation.

[10]  H. White,et al.  Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected Thrombolysis in Myocardial Infarction (TIMI) frame count and stenosis severity. , 1998, The American journal of cardiology.

[11]  J. Dodge,et al.  Thrombolysis in Myocardial Infarction frame count in saphenous vein grafts. , 1998, American heart journal.

[12]  F. Neumann,et al.  Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[13]  S. Ogawa,et al.  C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. , 1997, Circulation.

[14]  F. Neumann,et al.  Induction of cytokine expression in leukocytes in acute myocardial infarction. , 1997, Journal of the American College of Cardiology.

[15]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[16]  L. Horwitz,et al.  An antibody to leukocyte integrins attenuates coronary vascular injury due to ischemia and reperfusion in dogs. , 1997, The American journal of physiology.

[17]  E. Braunwald,et al.  TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. , 1997, Circulation.

[18]  R. Goldberg,et al.  Effect of elevated leukocyte count on in-hospital mortality following acute myocardial infarction. , 1996, The American journal of cardiology.

[19]  T. Springer,et al.  Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. , 1996, Blood.

[20]  E. Braunwald,et al.  TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.

[21]  S. Berliner,et al.  Increased adhesiveness of peripheral blood leukocytes corresponds to the appearance of expansion following anterior wall myocardial infarction , 1996, Clinical cardiology.

[22]  F. Neumann,et al.  Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. , 1995, Circulation.

[23]  D. Mann,et al.  Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. , 1994, Chest.

[24]  T Sandor,et al.  Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. , 1992, The American journal of cardiology.

[25]  M. Burr,et al.  Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). , 1992, European heart journal.

[26]  A. M. Lefer,et al.  Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. , 1991, The Journal of clinical investigation.

[27]  R. Kloner,et al.  Influx of Neutrophils Into the Walls of Large Epicardial Coronary Arteries in Response to Ischemia/Reperfusion , 1991, Circulation.

[28]  P C Elwood,et al.  Fibrinogen, Viscosity, and White Blood Cell Count Are Major Risk Factors for Ischemic Heart Disease: The Caerphilly and Speedwell Collaborative Heart Disease Studies , 1991, Circulation.

[29]  J. Dormandy,et al.  Leukocytes and the risk of ischemic diseases. , 1987, JAMA.

[30]  C. Forbes,et al.  White Blood Cell Count and Haematocrit as Predictors of Coronary Recurrence after Myocardial Infarction , 1985, Thrombosis and Haemostasis.

[31]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[32]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[33]  G. Schmid-Schönbein,et al.  Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. , 1983, The American journal of pathology.

[34]  R. Kloner,et al.  The "no-reflow" phenomenon after temporary coronary occlusion in the dog. , 1974, The Journal of clinical investigation.